# Lipocine (LPCN) — News

LPCN · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/lpcn/news

## Recent headlines

- [Orsl unit wins BPCL EPCOM pact for CBG plant in Hubli](https://www.ainvest.com/news/orsl-unit-wins-bpcl-epcom-pact-cbg-plant-hubli-2610) — AInvest Wire, Oct 12, 2026
  Oriana Power Limited has secured a contract to provide engineering, procurement, and construction (EPC) services for a compressed biogas (CBG) plant in Hubli, India. The project is part of a broader national initiative to expand domestic CBG production and reduce reliance on imported natural gas.…
- [Lipocine - Verity Pharma to launch Tlando in Canada by end of 2026 - SEC filing](https://www.ainvest.com/news/lipocine-verity-pharma-launch-tlando-canada-2026-sec-filing-2610) — AInvest Wire, Oct 7, 2026
  Lipocine Inc. (NASDAQ:LPCN) has announced plans to launch its testosterone therapy product, Tlando, in Canada by the end of 2026, according to a recent SEC filing. The company has partnered with Verity Pharma for the commercialization of the product in the Canadian market. Tlando, a novel oral…
- [Lipocine - Health Canada approves Tlando for testosterone replacement therapy in adult males - SEC filing](https://www.ainvest.com/news/lipocine-health-canada-approves-tlando-testosterone-replacement-therapy-adult-males-sec-filing-2610) — AInvest Wire, Oct 7, 2026
  Lipocine Inc. (NASDAQ: LPCN) has announced that Health Canada has approved TLANDO (testosterone undecanoate) for testosterone replacement therapy in adult males with conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism approval . TLANDO, a novel oral…
- [Lipocine - Bloom study plans to enroll about 120 participants with severe postpartum depression](https://www.ainvest.com/news/lipocine-bloom-study-plans-enroll-120-participants-severe-postpartum-depression-2609) — AInvest Wire, Sep 14, 2026
  Lipocine Inc. (NASDAQ: LPCN) has announced plans for the "Bloom" study, a clinical trial aiming to enroll approximately 120 participants with severe postpartum depression (PPD) to further evaluate the potential of its drug candidate, LPCN 1154. The study will build on recent Phase 3 trial results,…
- [Lipocine - First participant dosing in Bloom study expected in early Q4 2026](https://www.ainvest.com/news/lipocine-participant-dosing-bloom-study-expected-early-q4-2026-2609) — AInvest Wire, Sep 14, 2026

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).